Dynavax Announces HEPLISAV Data to Be Presented at IDSA Medical Conference
Data on HEPLISAV in Chronic Kidney Disease Patients
BERKELEY, Calif.--(BUSINESS WIRE)--Sep 22, 2009 - Dynavax Technologies Corporation (Nasdaq:DVAX) today announced that an abstract with chronic kidney disease patient data for HEPLISAVTM, an investigational adult hepatitis B vaccine, will be presented at the 47th Annual Meeting of the Infectious Disease Society of America (IDSA) in Philadelphia, Pennsylvania, from October 29 through November 1, 2009.
For more information on this conference, please visit the IDSA website at http://www.idsociety.org.
HEPLISAV is a Phase 3 investigational adult hepatitis B vaccine designed to provide increased, rapid protection with fewer doses than current licensed vaccines. Over 2,500 individuals have been vaccinated with HEPLISAV to date. Dynavax is developing HEPLISAV for populations that are less responsive to current licensed vaccines, including adults over 40 years of age, individuals with chronic kidney disease, and others.
Dynavax has worldwide commercial rights to HEPLISAV, which combines hepatitis B surface antigen (HBsAg) with a proprietary Toll-like Receptor 9 agonist to enhance the immune response.
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide more rapid and increased protection with fewer doses than current licensed vaccines. For more information visit www.dynavax.com.
Contact: Dynavax Technologies Corporation
Amy Figueroa, 510-665-7211
Investor Relations and Corporate Communications
Posted: September 2009